Extraintestinal Clostridium difficile infections.
Byl
B
B
Microbiology Department, Erasme University Hospital, Brussels, Belgium.
Jacobs
F
F
Struelens
M J
MJ
Thys
J P
JP
D000293:Adolescent; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000994:Antitrichomonal Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology*; D002442:Ceftazidime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000302:isolation & purification; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D005767:Gastrointestinal Diseases / Q000150:complications / Q000382:microbiology; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D014640:Vancomycin / Q000627:therapeutic use; D014947:Wounds and Injuries / Q000150:complications / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000994:Antitrichomonal Agents; D002511:Cephalosporins; D008795:Metronidazole; D014640:Vancomycin; D002442:Ceftazidime